// App-Quantinova.ai

: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate Responses to Apremilast at Week 24 in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Researchers

Presenter

  • April W Armstrong

Principal Investigators

  • Richard B Warren

  • Howard Sofen

  • Lynda Spelman

  • Craig Leonardi

  • Subhashis Banerjee

  • Tao Wang

  • John Throup

  • Elizabeth Colston

  • Andrew Napoli

  • Alexa B Kimball

Medical Centers

  • University of Southern California, Los Angeles, CA

  • University of Manchester, Manchester, United Kingdom

  • Dermatology Research Associates, Los Angeles, CA

  • Veracity Clinical Research and Probity Medical Research, Woolloongabba, QLD, Australia

  • Washington University School of Medicine, St. Louis, MO

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Harvard Medical School, Boston, MA

  • Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc, Boston

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved